Why the study?
Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events remains unclear.
What are the cardiac adverse event signals associated with quetiapine in a real-world pharmacovigilance database?
What are the cardiac adverse event signals associated with quetiapine in a real-world pharmacovigilance database?
Quetiapine is associated with early-onset cardiac adverse events, including 13 newly identified signals, highlighting the need for early cardiac monitoring after treatment initiation.
Answers are grounded in this paper and cite their sources.
Quetiapine cardiac AE signals, including 13 new ones, warrant vigilance in prescribing; leaves open causal risks pending prospective confirmation.
OBJECTIVE: Quetiapine, an atypical second-generation antipsychotic drug, is approved for treatment of schizophrenia, bipolar disorder, and depression. Due to the limitations of clinical trials, the association between quetiapine and rare cardiac adverse events (AEs) is still unclear. This study is to evaluate quetiapine-associated cardiac AEs through data mining of FDA Adverse Event Reporting System (FAERS). METHODS: Reporting odds ratio (ROR) was used to quantify the signals of quetiapine-related cardiac AEs from the first quarter (Q1) of 2018-2022 Q1. Serious and nonserious cases were compared, and signals were prioritized using a rating scale. RESULTS: A total of 1004 cases of quetiapine-associated cardiac AEs were identified, with 31 signals being detected, among which 13 AEs were identified as new and unexpected signals. Besides, nine and 22 cardiac AEs were identified as moderate and weak clinical priority. The median TTO for moderate and weak clinical priority signals were 0 and 4 days, respectively. All of the cardiac AEs had early failure type characteristics, suggesting that most of the patients developed cardiac AEs in a few days after quetiapine treatment, and that the risk of cardiac AEs occurrence would be gradually decreased over time. CONCLUSION: Our study provided valuable evidence for health-care professionals to mitigate the risk of quetiapine-associated cardiac AEs based on an extensive analysis of a real-world, large-sample FAERS database, and prioritize cardiac AE signals.
No takes yet. Share an insight, caveat, or question.
Shu et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: